- Home
- ACIU vs PRQR Comparison
ACIU vs PRQR Comparison
Compare ACIU & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- PRQR
- Stock Information
- Founded
- ACIU 2003
- PRQR 2012
- Country
- ACIU Switzerland
- PRQR Netherlands
- Employees
- ACIU N/A
- PRQR N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- ACIU Health Care
- PRQR Health Care
- Exchange
- ACIU Nasdaq
- PRQR Nasdaq
- Market Cap
- ACIU 189.1M
- PRQR 179.1M
- IPO Year
- ACIU 2016
- PRQR 2014
- Fundamental
- Price
- ACIU $2.04
- PRQR $2.35
- Analyst Decision
- ACIU Strong Buy
- PRQR Strong Buy
- Analyst Count
- ACIU 1
- PRQR 8
- Target Price
- ACIU $12.00
- PRQR $8.88
- AVG Volume (30 Days)
- ACIU 123.5K
- PRQR 357.1K
- Earning Date
- ACIU 08-05-2025
- PRQR 08-07-2025
- Dividend Yield
- ACIU N/A
- PRQR N/A
- EPS Growth
- ACIU N/A
- PRQR N/A
- EPS
- ACIU N/A
- PRQR N/A
- Revenue
- ACIU $32,014,254.00
- PRQR $21,212,711.00
- Revenue This Year
- ACIU N/A
- PRQR N/A
- Revenue Next Year
- ACIU $533.21
- PRQR N/A
- P/E Ratio
- ACIU N/A
- PRQR N/A
- Revenue Growth
- ACIU 91.20
- PRQR 85.91
- 52 Week Low
- ACIU $1.43
- PRQR $1.07
- 52 Week High
- ACIU $4.26
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- ACIU 54.21
- PRQR 66.90
- Support Level
- ACIU $1.94
- PRQR $2.10
- Resistance Level
- ACIU $2.15
- PRQR $2.18
- Average True Range (ATR)
- ACIU 0.16
- PRQR 0.13
- MACD
- ACIU -0.00
- PRQR 0.01
- Stochastic Oscillator
- ACIU 72.22
- PRQR 56.92
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.